

**Listing of Claims:**

This listing of the claims reflects the amendments made in the Submission Accompanying the Request for Continued Examination dated 12/16/2004.

Claim 128 (previously presented): A method of treating cancer of the respiratory tract in a patient in need of treatment which comprises administering by inhalation a pharmaceutically safe and effective amount of an aerosolized vesicant anti-cancer agent; wherein said vesicant anti-cancer agent is unencapsulated and wherein the particle size of said aerosol is from about 0.1  $\mu\text{m}$  to about 10.0  $\mu\text{m}$ .

Claim 129 (canceled)

Claim 130 (withdrawn)

Claim 131 (previously presented): The method according to Claim 151 wherein said alkylating agent anti-cancer agent is selected from the group consisting of mechlorethamine, mitomycin-C, dactinomycin, and mithramycin.

Claim 132 (withdrawn)

Claim 133 (withdrawn)

Claim 134 (withdrawn)

Claim 135 (previously presented): The method according to Claim 128 wherein said vesicant anti-cancer agent is administered by inhalation as an aerosolized liquid, powder or gas.

Claim 136 (previously presented): The method according to Claim 135 wherein said aerosolized vesicant anticancer agent is administered as an aerosolized liquid.

Claim 137 (previously presented): The method according to Claim 135 wherein said aerosolized vesicant is administered as an aerosolized powder.

Claim 138 (withdrawn)

Claim 139 (withdrawn)

Claim 140 (withdrawn)

Claim 141 (withdrawn)

Claim 142 (withdrawn)

Claim 143 (withdrawn)

Claim 144 (withdrawn)

Claim 145 (withdrawn)

Claim 146 (cancelled)

Claim 147 (previously presented): The method according to Claim 128 wherein the particle size of said aerosol is from about 1.0  $\mu\text{m}$  to about 5.0  $\mu\text{m}$ .

Claim 148 (previously presented): The method according to Claim 147 wherein the particle size of said aerosol is from about 2.0  $\mu\text{m}$  to about 2.5  $\mu\text{m}$ .

Claim 149 (withdrawn)

Claim 150 (withdrawn)

Claim 151 (previously presented): The method according to Claim 129 wherein said anti-cancer agent is an alkylating agent.

Claim 152 (previously submitted): The method according to Claim 131 wherein said alkylating agent is mechlorethamine.

Claim 153 (previously submitted): The method according to Claim 131 wherein said alkylating agent is mitomycin-C.

Claim 154 (previously submitted): The method according to Claim 131 wherein said alkylating agent is dactinomycin.

Claim 155 (previously submitted): The method according to Claim 131 wherein said alkylating agent is mithramycin.

Claim 156 (canceled)

Claim 157 (canceled)